...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Trying to get my head around this

Great question P1 and great answer Tada. 

Tada wrote "It is my understanding that the most tax efficient way to get the shareholders the money is to issue a new share for each share of ZC owned, just minutes before the sale closes, transfer the asset being sold into this new entity and then immediately sell that new share. This would all be done behind the scenes and our brokerage statements would show a new share being put into our accounts and then the same day or the next day that new share being redeemed for cash. ZC may or may not retain anything."

If ZE sells a compound, ZE could also just retain the $ to fund current and future ZE operations. No guarantee that the scenario Tada described would happen. Similarly, it is somewhat unclear and no guarantee that apabetalone royalties flowing to ZC would go directly to shareholders either. 

Share
New Message
Please login to post a reply